• No products in the list

CVD StripAssay A

Short description

The CVD StripAssay A is a diagnostic tool designed for the precise identification of genetic mutations associated with cardiovascular diseases. This assay utilizes polymerase chain reaction (PCR) and reverse-hybridization techniques to deliver accurate results for in vitro diagnostics. With coverage of eight crucial mutations, including Apo B R3500Q, Apo E2/E3/E4, Beta-Fibrinogen -455G>A, HPA1a/b (Gp IIIa; integrin beta 3 L33P), ACE 287 bp insertion/deletion (I/D), and eNOS -786T>C and 894G>T, it helps healthcare professionals and researchers to gain deeper insights into an individual’s genetic predisposition to CVD.

Product highlights

  • Apo B R3500Q
  • Apo E2/E3/E4
  • Beta-Fibrinogen -455G>A
  • HPA1a/b (Gp IIIa; integrin beta 3 L33P)
  • ACE 287 bp insertion/deletion (I/D)
  • eNOS -786T>C and 894G>T

Ask for a quote

CVD StripAssay A



Instructions for Use

Brochure StripAssays


For any missing information or if you require additional details, please do not hesitate to contact us. 

Specifications of the CVD StripAssay A

Overview of the CVD StripAssay A

The CVD StripAssay A is a specialized diagnostic tool used to identify genetic mutations linked to cardiovascular diseases (CVD). This assay combines polymerase chain reaction (PCR) and reverse-hybridization techniques to ensure precise and reliable results. It is primarily used for in vitro diagnostics.

Key Mutations Covered by the CVD StripAssay A

1. Apo B R3500Q: This mutation in the Apo B gene is associated with familial hypercholesterolemia, a condition that can lead to high cholesterol levels and increased risk of CVD.
2. Apo E2/E3/E4: The Apo E gene has three common alleles (E2, E3, and E4) that influence lipid metabolism. Variations in these alleles are linked to different risks of developing cardiovascular diseases.
3. Beta-Fibrinogen -455G>A: This genetic variation affects the production of fibrinogen, a protein involved in blood clotting. Changes in fibrinogen levels can impact clot formation and cardiovascular risk.
4. HPA1a/b (Gp IIIa; integrin beta 3 L33P): This mutation affects platelet glycoproteins, influencing platelet aggregation and the risk of thrombotic events.
5. ACE 287 bp insertion/deletion (I/D): The insertion or deletion of a 287 base pair sequence in the ACE gene impacts the levels of angiotensin-converting enzyme, which plays a role in blood pressure regulation and cardiovascular health.
6. eNOS -786T>C and 894G>T: These mutations in the endothelial nitric oxide synthase (eNOS) gene affect the production of nitric oxide, a molecule crucial for vascular function. Variations can lead to endothelial dysfunction and increased CVD risk.

Applications and Benefits
Personalized Medicine: By identifying genetic mutations associated with CVD, healthcare professionals can tailor prevention and treatment strategies to the individual’s genetic profile.
Early Detection: Early identification of genetic predispositions allows for proactive management of cardiovascular risk factors, potentially reducing the incidence of CVD

In conclusion, the CVD StripAssay A is a powerful diagnostic tool that leverages advanced genetic techniques to provide detailed insights into an individual’s risk of developing cardiovascular diseases. By identifying key genetic mutations, it supports personalized healthcare and contributes to ongoing research in the field of cardiology.


Components of the CVD StripAssay A
  • Lysis Solution (50 ml)
  • GENXTRACTTM Resin (5 ml)
  • Amplification Mix (yellow cap, 500 µl)
  • Taq Dilution Buffer (transparent cap, 500 µl)
  • DNAT (blue cap, 1.5 ml)
  • Typing Trays (3)
  • Teststrips (20)
  • Hybridization Buffer (white cap, 25 ml)
  • Wash Solution A (white cap, 80 ml)
  • Conjugate Solution (25 ml)
  • Wash Solution B (80 ml)
  • Color Developer (25 ml)
  • CollectorTM Sheet (1)

Explore Related Items